Summit Therapeutics says ivonescimab plus chemotherapy cuts death risk 25% in Phase III trial
SMMT•Summit Therapeutics said ivonescimab with chemotherapy improved overall survival versus durvalumab with chemotherapy in first-line advanced biliary tract cancer, cutting death risk 25% in a Phase III trial. The regimen also delayed disease progression, with a manageable safety profile and no additional safety signals.
1. Trial results
Summit Therapeutics announced that ivonescimab with chemotherapy improved overall survival versus durvalumab with chemotherapy in first-line advanced biliary tract cancer. Results from partner Akeso’s China-based Phase III HARMONi-GI1 trial are being presented at the ESMO 2026 Congress in Madrid. The regimen also delayed disease progression, with a manageable safety profile and no additional safety signals.
2. US trial plans
A US registration-enabling Phase II/III trial with ECOG-ACRIN is expected to begin site activation in the fourth quarter of 2026. Ivonescimab remains investigational in the United States and Europe.
